7th Annual CAR-T Summit
Cell and gene therapy (CGT), including chimeric antigen receptor (CAR) T-cell therapy represents a new frontier in the fight against rare genetic disorders and cancers.
Complex study designs, challenging patient populations and distinct operational delivery requirements are the norm in CGT clinical trials. New treatment approaches are often unfamiliar to investigators, site staff and patients alike.
The Syneos Health Cell and Gene Therapy Consortium, built upon nearly two decades of experience in the field, is the hub for our knowledge and experience base in CGT preclinical/clinical development and commercialization, including CAR-T trials. It brings together the cross-functional capabilities needed to navigate the challenges unique to cell therapy trials, accelerate their development and deliver on their promise.
Meet with us at the 7th Annual CAR-T Summit to discuss how our collective knowledge and insights can be fully leveraged to deliver solutions specific to the needs of your trial—and make each study as safe and effective for patients as possible.
Panel Discussion | September 20 | 2:45 PM
Developing Safer Cell Therapies for Critically Ill Patients in Need
|
Panelist Dr. Wael Harb Vice President Medical Affairs, Syneos Health |
 |
